Assaying Potency of Novel Vaccines
R. Sheets
DOI: https://doi.org/10.1586/14760584.5.3.315
2006-06-01
Expert Review of Vaccines
Abstract:Determining appropriate measures of potency for vaccines has always been challenging. Doing so is even more challenging for novel vaccines, such as HIV/AIDS, tuberculosis and malaria, for which there are no good animal models or accepted correlates of immune protection. A workshop was held in October 2005 in Bethesda, MD, USA to present data on assays being developed to measure the potency of novel vaccines and to consider key questions, including whether vector replication and in vitro expression were adequate measures of vector potency and how the potency of vaccines used in heterologous prime–boost strategies should be determined. During a roundtable discussion, the delegates agreed that potency assays for such novel vaccines are unlikely to be efficacy indicating, but instead will be one tool used by the manufacturers for assessing manufacturing consistency, product stability and bridging changes in manufacturing. It was generally agreed that potency assay parameters currently being used to support Phase I clinical trials, such as vector replication, in vitro expression and other physical parameters (e.g., percentage supercoiled for plasmid vectors) are appropriate measures of vaccine potency, potentially even for Phase III and licensure. Furthermore, it was agreed that the potency of heterologous prime–boost vaccines should be measured separately rather than one being contingent on the other, even though the combination may be required to achieve human efficacy. On October 11–12, 2005, the Division of AIDS (DAIDS, MD, USA), the Division of Microbiology and Infectious Diseases (DMID, MD, USA), the Vaccine Research Center (VRC, MD, USA) of the National Institute of Allergy and Infectious Diseases (NIAID) and the Office of AIDS Research (OAR), NIH (MD, USA), along with the Center for Biologicals Evaluation and Research (CBER)/US FDA (MD, USA), International AIDS Vaccine Initiative (IAVI, NY, USA), and the WHO/UNAIDS (Switzerland) coorganized a workshop on Assaying Potency of Novel Vaccines [101]. Although the workshop focused on vaccines for malaria, tuberculosis and HIV/AIDS, novel potency assays for other vaccines were considered and the conference attempted to address key questions that are, in a more general sense relevant to all of these novel vaccines. Key questions to be addressed included: